We are independent & ad-supported. We may earn a commission for purchases made through our links.

Advertiser Disclosure

Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.

How We Make Money

We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently from our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.

What is Chronic Myelomonocytic Leukemia?

K.C. Bruning
By
Updated Mar 03, 2024
Our promise to you
TheHealthBoard is dedicated to creating trustworthy, high-quality content that always prioritizes transparency, integrity, and inclusivity above all else. Our ensure that our content creation and review process includes rigorous fact-checking, evidence-based, and continual updates to ensure accuracy and reliability.

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

Editorial Standards

At TheHealthBoard, we are committed to creating content that you can trust. Our editorial process is designed to ensure that every piece of content we publish is accurate, reliable, and informative.

Our team of experienced writers and editors follows a strict set of guidelines to ensure the highest quality content. We conduct thorough research, fact-check all information, and rely on credible sources to back up our claims. Our content is reviewed by subject matter experts to ensure accuracy and clarity.

We believe in transparency and maintain editorial independence from our advertisers. Our team does not receive direct compensation from advertisers, allowing us to create unbiased content that prioritizes your interests.

Chronic myelomonocytic leukemia (CMML) is a condition in which the body creates an excessive number of immature white blood cells, known as myeloblasts and myelocytes. These cells impede the formation of monocytes, which both fight infection and help other blood cells in the body to implement immunity. The extra cells also cause havoc in the body by taking up space needed in the bone marrow for platelets and red blood cells. As a result, a patient can suffer several problems including anemia, infection, or the tendency to bleed easily.

The condition is most common among older males. It is most commonly caused by environmental elements, chemicals, and exposure to radiation. Some cases of chronic myelomonocytic leukemia are also attributed to the use of some kinds of anticancer medications. The severity of the condition depends on the number of immature while blood cells, or blasts, in the bone marrow or blood; chromosomal changes; how many platelets or white blood cells are in the bone marrow and blood; and whether the patient has anemia.

There are two primary types of chronic myelomonocytic leukemia, which are distinguished by what percentage of blasts are in the bone marrow and blood, type CMML-1 and CMML-2. Type CMML-1 indicates there are less than 10 percent blasts present in the bone marrow and five percent that exist in the blood. The CMML-2 type typically has a range of 10 to 19 percent bone marrow blasts and five to 19 percent blood blasts.

Symptoms of chronic myelomonocytic leukemia include anemia, a sensation of fullness under the ribs, and an enlarged spleen or liver. Some patients may get leucopenia, an infection caused by a low white blood cell count. Other signs of CMML include bruising and bleeding caused by insufficient counts of platelets and pinpoints of blood coming from the skin known as petechiae.

Chronic myelomonocytic leukemia is usually not curable. It can be treated with drugs such as cytarbine, decitabine, and imatinib, depending on the nature of the condition. If an adequate donor can be found, a stem cell transplant can sometimes cure CMML, particularly in juvenile patients.

The average patient who is diagnosed with chronic myelomonocytic leukemia is expected to live from one to two years after treatment commences. Some factors work against patient survival rate, including a large spleen, severe anemia, and a high lactate dehydrogenase (LDH) level. Survival is also less likely for patients who have a high number of blasts or who have an abnormally high count of white blood cells overall. In some patients who are not cured, CMML could turn into acute myelogenous leukemia (AML).

TheHealthBoard is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.
K.C. Bruning
By K.C. Bruning
Kendahl Cruver Bruning, a versatile writer and editor, creates engaging content for a wide range of publications and platforms, including TheHealthBoard. With a degree in English, she crafts compelling blog posts, web copy, resumes, and articles that resonate with readers. Bruning also showcases her passion for writing and learning through her own review site and podcast, offering unique perspectives on various topics.

Discussion Comments

K.C. Bruning

K.C. Bruning

Kendahl Cruver Bruning, a versatile writer and editor, creates engaging content for a wide range of publications and platforms, including TheHealthBoard. With a degree in English, she crafts compelling blog posts, web copy, resumes, and articles that resonate with readers. Bruning also showcases her passion for writing and learning through her own review site and podcast, offering unique perspectives on various topics.
TheHealthBoard, in your inbox

Our latest articles, guides, and more, delivered daily.

TheHealthBoard, in your inbox

Our latest articles, guides, and more, delivered daily.